Followers | 196 |
Posts | 24614 |
Boards Moderated | 0 |
Alias Born | 04/03/2010 |
Saturday, August 27, 2022 7:34:38 PM
First of all, the combination trial is a Phase 1 trial, so your notions and ideas are nonsensical. The measure is whether Keytruda helps these patients, not DCVax-L. DCVax-L is effectively the placebo in this trial.
So what they are measuring here is quite complex and doesn't fit your description, but more importantly, they'd not be able to get a measure without waiting 5 years for the last patient to get it if it was purely OS, and again, this is a Phase I combination trial to measure the impact of Keytruda as an additional drug. This is for recurrent patients and they have effectively already shown that for recurrent patients, DCVax-L has a significant impact on OS by itself.
They have numerous measures, all listed, not just one, and they will look at the range of different biomarkers and measures. The primary measure is NOT PFS, nor is it OS.
The SECONDARY measures are OS and PFS, with PFS at 6 months, measured very carefully by a newer standard to avoid the problems they encountered previously. Moreover, there are numerous other measures. Presumably DCVax-L will be already approved when that study is fully evaluated for the effects of the combination, based on a wide range of measures, including biomarkers, that were not fully understood or available on the DCVax-L Phase 3 when it started. Indeed, the primary measures appear to be biomarker measures.
Additionally, since the start of the Phase 3 trial, they have worked on identifying pseudoprogression and have protocols for avoiding what happened there at the start of the trial because they had no way to distinguish what was an unknown complexity introduced by immunotherapies, which trigger immune reactions such as inflation, that can be misidentified by doctors not aware of the disease process with DCVax-L
It's really a silly comment.
Also, DCVax-L is the placebo arm in this trial effectively. So the measures are to measure how Keytruda impacts these things, when given in combination with DCVax-L, which is the baseline treatment (standard of care in this trial) for these recurrent patients, in this trial. Also something your point, HyGro, ignores. It's quite critical to understanding what's actually going on here. Additionally, the Principal Investigator is Timothy F Cloughesy. Just FYI.
More on measuring to avoid pseudoprogression:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499019/
Another problem with some drugs is that using the old standards for measurement, they reduced inflammation, without extending survival, and this came to be known as "pseudoresponse", meaning false response. The FDA is also concerned with this for some of the other drugs that were approved based on PFS and other proxy measures for survival, on an accelerated basis, but then those drugs did not extend survival. Keytruda and Opdivo were re-evaluated because of this just last year.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM